新着Pick
1Pick
Pick に失敗しました

選択しているユーザー
Researchers from the Sheba Medical Centre in Tel Aviv studied the immune response in 102 hospital staff members who received both Pfizer/BioNTech vaccine shots.

They found that 100 people developed up to 20 times more antibodies within a week of the second dose than COVID-19 survivors who went through severe COVID-19 cases.

These higher levels of antibodies that would neutralize the actual virus upon actual encounter are believed to also prevent transmission.

The higher the number of antibodies, the harder it would be for the virus to infect cells and replicate enough for vaccinated people to become infected.